Q1 net loss $9.1M ($0.54/sh); cash $226.6M; HPI opt-in decision pending mid-2026

ASSEMBLY BIOSCIENCES, INC.

2026-Q1 EPS reported -$0.54 revenue$8,213,000

Net loss $9.1M ($0.54/share) vs $8.8M ($1.17/share) in Q1 2025; cash $226.6M at quarter end.
Gilead collaboration revenue $8.2M, down from $9.4M YoY; R&D expenses flat at $14.9M.
Completed Phase 1b for ABI-5366/1179 (genital herpes); to decide on 40% U.S. cost-profit share opt-in by mid-2026.
Completed chronic tox for ABI-6250 (HDV entry inhibitor); Phase 2 start expected Q4 2026.
Cash runway projected into 2028.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ASSEMBLY BIOSCIENCES, INC. reported the quarter ended March 31, 2026 results: revenue $8.2 million, net income Net loss attributable to common stockholders was $9.1 million, or $0.54 per basic and diluted share, EPS $0.54 per basic and diluted share.

Period: the quarter ended March 31, 2026
Revenue: $8.2 million
Net income: Net loss attributable to common stockholders was $9.1 million, or $0.54 per basic and diluted share
EPS: $0.54 per basic and diluted share
Result: reported results

Exact text from the filing

compared to $248.1 million as of December 31, 2025. The company’s cash position is projected to fund operations into 2028. • Revenue from collaborative research with Gilead was $8.2 million for the three months ended March 31, 2026, compared to $9.4 million for the same period in 2025. The decrease reflects the timing of activities performed and progress toward

View on SEC.gov

Browse all earnings releases →

ASSEMBLY BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-211922

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.